Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Amylyx Pharmaceuticals and Mitsubishi Tanabe Pharma America
Description:
Amyotrophic lateral sclerosis (ALS), more commonly known as Lou
Gehrig’s disease, is a progressive neurodegenerative disease that
affects nerve cells in the brain and the spinal cord. An estimated
20,000 people in the United States are living with ALS. It is a
progressive disease in which the motor neurons eventually die.
Mortality is usually the result of respiratory failure. Although
most patients with ALS die within 3 to 5 years after symptoms first
appear, about 20% of patients with ALS will live 5 years, 10% will
live 10 years, and about 5% will live 20 years or more. Currently,
there is no cure for ALS. Fortunately for patients with ALS, the
treatment paradigm has expanded in recent years, and more options
are on the horizon, giving medical directors and clinicians many
more options in improving survival benefit, managing symptoms and
delaying progression in the ALS patient population.
Upon completion of this
activity, participants will be able to:
-
Examine the clinical and economic
burden of ALS in terms of health care resource utilization,
indirect costs, and member quality of life
-
Analyze the underlying
pathophysiology of ALS and the barriers to accurate and early
diagnosis
-
Evaluate the value of appropriate,
evidence-based drug therapy for slowing disease progression,
improving survival, and minimizing direct expenditures in other
categories
-
Explore the role of new and emerging
therapies in the management of patients with ALS and strategies
to integrate them into the treatment paradigm
-
Discuss the role of novel oral
therapy administration in the management of patients with ALS
-
Assess the managed care
considerations of new and emerging therapies by exploring where
these agents fit in the evolving ALS treatment paradigm
|
Faculty: |
Jinsy A. Andrews, MD,
MSc, FAAN
Associate Professor of Neurology, Division of
Neuromuscular Medicine
Director of Neuromuscular Clinical Trials
Columbia University Irving Medical Center |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Andrews has served as a consultant for Affinia,
Amylyx, Apellis, Biogen, Cytokinetics, Denali,
Neurosense, Novartis, Orphazyme, QurALis, Sanofi, UCB,
and Wave Life Sciences. She has received grant/research
support from Alexion, Amylyx, AZTherapies, Biogen,
Biohaven, Clene, Cytokinetics, MGH Foundation, Novartis,
Orion, Prilenia, and Ra Pharma. Her presentation has
been reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
Amylyx Pharmaceuticals and Mitsubishi Tanabe Pharma America
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |